Roche: FDA grants priority review to entrectinb

(CercleFinance.com) - Swiss pharma group Roche said the US Food and Drug Administration granted priority review to its personalised medicine entrectinib for the treatment of metastatic solid tumours and lung cancer.


The FDA has accepted the company's new drug applications and granted priority review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC), the drugmaker said.

The FDA is expected to make a decision on approval by August 2019.

Copyright (c) 2019 CercleFinance.com. All rights reserved.